BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 P&L / Income Statement

BIOCRYST PHARMACEUTICALS, INC. (BCRX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service (Schedule of Revenues). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

374,663,000 US dollars

Cost of product sales

9,217,000 US dollars

Gross profit (calculated)

365,446,000 US dollars

Operating expenses (calculated)

968,579,000 US dollars

Income (loss) from operations

negative 603,133,000 US dollars

Total other expense, net

negative 38,201,000 US dollars

Income (loss) before income taxes

negative 641,334,000 US dollars

Income tax expense

2,083,000 US dollars

Net income (loss)

negative 643,417,000 US dollars

ORLADEYO

306,549,000 US dollars

License and other revenues

68,114,000 US dollars

Acquired in-process research and development

697,761,000 US dollars

Research and development

112,288,000 US dollars

Selling, general and administrative

158,530,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.